HUMAN RECOMBINANT HYPOSIALYLATED ERYTHROPOIETIN, METHODS OF PURIFICATION AND THERAPEUTIC USES THEREOF

摘要

The present invention relates to the fields of biotechnology and medicine and describes a pharmaceutical composition of recombinant human erythropoietin having a microheterogeneity of fucosylated N-glycans formed by bi, tri and tetra-antennary structures with mono and bi-sialylated sialic acid residues that represent 40-60% of the total glycans, trisialylated ones that represent 40-43% of the total glycans, and tetrasialylated ones that represent 10-13% of the total glycans. This glycosylation pattern confers properties to said composition that allow for its use in disorders of the nervous system. The invention also relates to the method of obtaining said pharmaceutical composition.